Document is current
Any future updates will be listed below
-
Authors
Nabet, Behnam http://orcid.org/0000-0002-6738-4200
Roberts, Justin M. http://orcid.org/0000-0001-6112-7476
Buckley, Dennis L.
Paulk, Joshiawa
Dastjerdi, Shiva
Yang, Annan
Leggett, Alan L.
Erb, Michael A. http://orcid.org/0000-0001-9993-3481
Lawlor, Matthew A.
Souza, Amanda
Scott, Thomas G.
Vittori, Sarah
Perry, Jennifer A.
Qi, Jun
Winter, Georg E.
Wong, Kwok-Kin
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Bradner, James E. http://orcid.org/0000-0002-2718-4415
- License Information
-
More Information
Article History
Received: 17 May 2017
Accepted: 2 February 2018
First Online: 26 March 2018
Competing interests
: The authors claim the following competing financial interests: International Patent Application Nos. PCT/US2016/039048, PCT/US2016/046087, PCT/US2016/046088, PCT/US2016/046089, each filed in the name of Dana-Farber Cancer Institute, Inc. D.L.B., J.P., and A.S. are now employees of Novartis. G.E.W. is a consultant for C4 Therapeutics. N.S.G. is a Scientific Founder and member of the Scientific Advisory Board of Syros Pharmaceuticals, C4 Therapeutics, and Petra Pharmaceuticals and is the inventor on IP licensed to these entities. J.E.B. is a Scientific Founder of Syros Pharmaceuticals, SHAPE Pharmaceuticals, Acetylon Pharmaceuticals, Tensha Therapeutics (now Roche), and C4 Therapeutics and is the inventor on IP licensed to these entities. J.E.B. is now an executive and shareholder in Novartis AG.
